Literature DB >> 12407432

Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse.

M Miglino1, G Berisso, R Grasso, L Canepa, M Clavio, I Pierri, D Pietrasanta, S Gatto, R Varaldo, F Ballerini, S Verdiani, L Casarino, F DeStefano, M Sessarego, A Dominietto, A M Raiola, S Bregante, C di Grazia, M Gobbi, A Bacigalupo.   

Abstract

We developed a PCR-based method to monitor clonogenic IgH VDJ rearrangement as a possible predictor of relapse in patients with acute B-ALL after allogeneic bone marrow transplantation (BMT). We studied 23 patients at diagnosis, before and after BMT. At the time of BMT, 13 patients were in first complete remission, eight in second complete remission and two in relapse. Four patients were PCR negative before BMT and remained PCR negative also after BMT (-/- pattern). They are still in remission after a median follow-up of 41 months. Nineteen patients were MRD-positive before BMT: three were PCR negative at first determination after BMT (+/- pattern) and maintain remission. Sixteen patients were PCR-positive at first determination after BMT (+/+ pattern): five became PCR negative (+/+/- pattern) (four with chronic graft-versus-host disease (GVHD) and two after donor lymphocyte infusions (DLI)). Nine patients remained PCR-positive (+/+/+ pattern) (four remain in remission, and six relapsed); two patients died before transplant. In conclusion, PCR negative patients before BMT remained negative post-BMT; many pre-BMT positive patients had initial MRD positivity after BMT: 37% of them achieved a molecular remission with cGVHD or DLI.

Entities:  

Mesh:

Year:  2002        PMID: 12407432     DOI: 10.1038/sj.bmt.1703659

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

1.  Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival.

Authors:  Veronika Bachanova; Michael J Burke; Sophia Yohe; Qing Cao; Karamjeet Sandhu; Timothy P Singleton; Claudio G Brunstein; John E Wagner; Michael R Verneris; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2012-03-16       Impact factor: 5.742

2.  Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma.

Authors:  Alex F Herrera; Haesook T Kim; Katherine A Kong; Malek Faham; Heather Sun; Aliyah R Sohani; Edwin P Alyea; Victoria E Carlton; Yi-Bin Chen; Corey S Cutler; Vincent T Ho; John Koreth; Chitra Kotwaliwale; Sarah Nikiforow; Jerome Ritz; Scott J Rodig; Robert J Soiffer; Joseph H Antin; Philippe Armand
Journal:  Br J Haematol       Date:  2016-10-06       Impact factor: 6.998

3.  Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL.

Authors:  M Eefting; C J M Halkes; L C de Wreede; C M van Pelt; S Kersting; E W A Marijt; P A von dem Borne; R Willemze; H Veelken; J H F Falkenburg
Journal:  Bone Marrow Transplant       Date:  2013-08-12       Impact factor: 5.483

Review 4.  How I Use Measurable Residual Disease in the Clinical Management of Adult Acute Lymphoblastic Leukemia.

Authors:  Fiona Fernando; Harry Frederick Robertson; Sarah El-Zahab; Jiří Pavlů
Journal:  Clin Hematol Int       Date:  2021-11-29

5.  Focused CRISPR-Cas9 genetic screening reveals USO1 as a vulnerability in B-cell acute lymphoblastic leukemia.

Authors:  Amit Kumar Jaiswal; Hellen Truong; Tiffany M Tran; Tasha L Lin; David Casero; Michael O Alberti; Dinesh S Rao
Journal:  Sci Rep       Date:  2021-06-23       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.